HLS Therapeutics Inc. (HLTRF)
OTCMKTS · Delayed Price · Currency is USD
3.362
-0.068 (-1.98%)
At close: Jan 8, 2026
HLS Therapeutics Revenue
HLS Therapeutics had revenue of $13.51M in the quarter ending September 30, 2025, a decrease of -4.08%. This brings the company's revenue in the last twelve months to $55.85M, down -1.92% year-over-year. In the year 2024, HLS Therapeutics had annual revenue of $56.62M, down -10.23%.
Revenue (ttm)
55.85M
Revenue Growth
-1.92%
P/S Ratio
1.85
Revenue / Employee
607.03K
Employees
92
Market Cap
103.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.62M | -6.46M | -10.23% |
| Dec 31, 2023 | 63.07M | 1.61M | 2.61% |
| Dec 31, 2022 | 61.47M | 1.46M | 2.43% |
| Dec 31, 2021 | 60.01M | 3.90M | 6.95% |
| Dec 31, 2020 | 56.11M | 1.95M | 3.60% |
| Dec 31, 2019 | 54.16M | -7.26M | -11.81% |
| Dec 31, 2018 | 61.42M | -13.67M | -18.20% |
| Dec 31, 2017 | 75.08M | 21.05M | 38.96% |
| Dec 31, 2016 | 54.03M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| The Cannabist Company Holdings | 349.84M |
| Jushi Holdings | 260.43M |
| MariMed | 157.38M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
| Growth Stalk Holdings | 583.34K |
HLS Therapeutics News
- 3 months ago - Esperion Partner HLS Receives Health Canada Approval For NILEMDO To Lower LDL-Cholesterol - Nasdaq
- 3 months ago - HLS Therapeutics Inc (HLTRF) Q3 2025 Earnings Call Highlights: Strong Profitability Growth Amid ... - GuruFocus
- 3 months ago - Q3 2025 HLS Therapeutics Inc Earnings Call Transcript - GuruFocus
- 3 months ago - HLS Therapeutics Inc. (HLS:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - HLS Therapeutics Inc. 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - HLS Therapeutics GAAP EPS of -$0.12, revenue of $13.5M - Seeking Alpha
- 3 months ago - HLS Therapeutics Announces Q3 2025 Financial Results - Benzinga
- 6 months ago - HLS Therapeutics announces new credit agreement - Seeking Alpha